Home About us Contact
|
Home About us Contact | ||
|
|
||
Adjacent Mucosa (adjacent + mucosa)
Selected AbstractsExpression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck,HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Issue 7 2009Ohad Ronen MD Abstract Background. Ubiquitin-conjugating enzyme (Ubc9) is a novel enzyme involved in posttranslational modification of cellular proteins. The objective of this study was to determine the expression of Ubc9 in squamous cell carcinoma of the head and neck (SCCHN). Methods. SCCHN specimens were stained with anti-Ubc9 antibodies, scored using a semiquantitative method, and statistically analyzed. Results. Forty-six tumors were stained, 26 of which included adjacent mucosa. Ubc9 was significantly upregulated in the malignant and peritumoral tissues compared with mucosa from normal individuals. In peritumoral tissues, Ubc9 expression was detected in the basal and suprabasal epithelial layers. No Ubc9 was detected in epithelial cells in normal mucosa. These differences in Ubc9 expression were statistically significant (p < .0001). Tumor Ubc9 expression significantly correlated with clinical and pathologic stage. Conclusions. Ubc9 is significantly overexpressed in the primary SCCHN tumors and peritumoral mucosa compared with normal epithelial cells. These findings suggest that Ubc9 may play an important role in tumorigenesis and tumor progression of SCCHN. © 2009 Wiley Periodicals, Inc. Head Neck, 2009 [source] Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinomaINTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Issue 4 2005Flavia R. R. Mangone Summary The activating protein-1 (AP-1) family of transcription factors has been implicated in the control of proliferation and differentiation of keratinocytes, but its role in malignant transformation is not clear. The aim of this study is to assess the pattern of mRNA expression of jun-fos AP-1 family members in 45 samples of head and neck squamous cell carcinomas (HNSCC) and matched adjacent mucosa by means of Northern blot analysis. Transcripts of all family members were identified, except for JunB that was detected only by means of reverse transcription polymerase chain reaction. Neither c-Fos nor JunD or FosB mRNA differed between tumours and normal tissues. We observed a strong Fos-related antigen-1 (Fra-1) and Fra-2 expression, but only Fra-1 mRNA densitometric values were higher in tumour, compared to normal adjacent mucosa (t -test, P = 0.006). A direct relationship between the positive expression of Fra-1 mRNA, above tumour median, was associated with the presence of compromised lymph nodes (Fischer exact test, P = 0.006). In addition, Fra-1 protein staining was assessed in a collection of 180 tumours and 29 histologically normal samples adjacent to tumours in a tissue array. Weak reactivity, restricted to the basal cell layer, was detected in 79% of tumour adjacent normal tissues, opposed to the intense reactivity of cancer tissues. In the subgroup of oral cancers, we have observed a shift in Fra-1 immunoreactivity, as long as the number of patients in each category, cytoplasmic or nuclear/cytoplasmic staining, was analysed (Fischer exact test, P = 0.0005). Thus, Fra-1 gene induction and accumulation of Fra-1 protein may contribute to the neoplastic phenotype in HNSCC. [source] The expression of NMDA receptor 1 is associated with clinicopathological parameters and prognosis in the oral squamous cell carcinomaJOURNAL OF ORAL PATHOLOGY & MEDICINE, Issue 9 2004S.-W. Choi Background:, Glutamate activates the N -methyl- d -aspartate (NMDA) receptors and this receptor is involved in the proliferation and migration of various tumour cells in vitro. However, the relationship between NMDA receptor expression and clinical parameters in cancer patients is unclear. Therefore, NMDA receptor 1 (NMDAR1) expression along with its clinical significance was examined in patients with oral squamous cell carcinoma (OSCC). Methods:, Eighty-one tumour specimens from OSCC patients were used to determine the NMDAR1 expression level by immunohistochemical staining. The control was obtained from a matched normal adjacent mucosa. The cases were considered to be positive if reactivity was displayed in >25% of the cells. Results:, The NMDAR1 reactivity was positive in 50 of 81 cases, while it was negative in the control. NMDAR1 expression was significantly associated with a lymph node metastasis (P = 0.008), the tumour size (P < 0.001), and the cancer stage (P = 0.034). The patients whose tumours expressed NMDAR1 had a significantly poorer survival than the patients who were NMDAR1-negative (log-rank = 6.45, d.f. = 1, P = 0.011). Conclusions:, The NMDAR1 overexpression was significantly associated with the prognosis-related factors. Therefore, it might be one of the prognostic markers of OSCC. [source] Transforming growth factor ,1 (TGF,1) expression in head and neck squamous cell carcinoma patients as related to prognosisJOURNAL OF ORAL PATHOLOGY & MEDICINE, Issue 3 2003Angela F. Logullo Abstract Background:, Transforming growth factor ,1 (TGF,1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGF,1 responsiveness is a critical step in epithelial carcinogenesis. Objective:, To investigate the prognostic relevance of TGF,1 expression in head and neck squamous cell carcinoma (HNSCC). Materials and methods:, TGF,1 distribution was determined by immunohistochemistry in oral cavity/oropharynx (n = 79), larynx (n = 36) and hypopharynx (n = 25) tumors and in matched normal adjacent mucosa. TGF,-type I and II receptors were determined in 20 cases of differentiated oral cavity/hypopharynx tumors. Cases were considered positive if displaying reactivity in >10% of the cells. Results:, TGF,1-positive expression was found in 47.2% of larynx, 36.7% of oral cavity/oropharynx and in 24% of the hypopharynx tumors. Reactivity in >60% of the cells was displayed only by 11.4% of HNSCC. All normal controls were positive. TGF,1-positive expression did not correlate with clinico pathological parameters. An association with differentiation was verified only in oral cavity/oropharynx tumors (P , 0.001). TGF,1 was also not related to 5 years survival (Kaplan,Meier). Strong and diffuse expression of TGF,-RII was identified in 19/20 cases regardless of TGF,1 immunoreactivity. Out of 17 TGF,1-positive oral cavity/oropharynx tumors, only nine expressed TGF,-RI suggesting a disruption of the TGF,1 pathway. We conclude that TGF,1 protein immunostaining is not a useful biomarker in assessment of prognosis in HNSCC. [source] Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study,APMIS, Issue 9 2005EUI JIN LEE Four cases of very rare composite glandular-endocrine cell carcinoma of the stomach are presented with methylation findings. All but one of the tumors arose in the antrum and two of them were at the early stage. Each composite carcinoma was accompanied by atrophic and metaplastic gastritis in the adjacent mucosa. Three cases showed lymph nodes metastasis, and one of them showed both glandular and neuroendocrine tumor components within the metastatic nodes. Mucin stains were positive in the adenocarcinoma areas while only the neuroendocrine markers were positive in neuroendocrine tumor components. Of all seven markers tested for, p16INK4A methylation was observed in both components of one composite carcinoma and hMLH1 was methylated in the neuroendocrine tumor component within the same tumor. An additional six gastric large cell neuroendocrine carcinomas showed no methylation. Follow up of patients indicated short survival in patients with poorly differentiated neuroendocrine carcinoma components and advanced stages of tumors, while patients with well-differentiated neuroendocrine tumor components and early stages showed long disease-free survival. Our results suggest that hypermethylation of tumor suppressor genes is rare in gastric composite and neuroendocrine carcinomas, and prognosis of gastric composite carcinomas appears to be related to the histopathology of neuroendocrine components and tumor stage. [source] Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck,APMIS, Issue 9 2004J. G. ERIKSEN Integrins and cadherins are cell adhesion molecules suggested to play an important role in malignant progression and tumour differentiation. Our aim was to characterise the pattern of expression and the relations between integrin ,1, ,4, ,6 and E-cadherin and the different histopathological features important when judging tumour differentiation, using a well-defined scoring system. Formalin-fixed paraffin-embedded pre-irradiation biopsies from 85 patients with head and neck squamous cell carcinomas (HNSCC) were stained and evaluated for the expression of integrin ,1, ,4 and ,6 and E-cadherin. The integrins were upregulated in carcinomas compared to the adjacent mucosa and E-cadherin was downregulated. However, differences were found within the tumour: Expression of E-cadherin was lost and the three integrins were upregulated at the tumour borders, compared to central parts of the tumour biopsy. Expression of the integrins did not correlate with tumour or histopathological parameters, whereas expression of E-cadherin was correlated with high degree of keratinisation, high nuclear maturation and few mitoses , factors that characterise well-differentiated carcinomas -and E-cadherin can therefore be considered as a marker of differentiation. Furthermore, loss of adhesion expressed by low E-cadherin and integrin ,4 correlated with the presence of nodal metastases at the time of diagnosis. [source] | ||||||||||